ClinicalTrials.gg
TerminatedNCT02963064Updated Jul 28, 2025

JSP191 Antibody Targeting Conditioning in SCID Patients

A Phase 1/2 interventional study of Humanized anti-CD117 Monoclonal Antibody (JSP191) in SCID, sponsored by Jasper Therapeutics, Inc.. Terminated at 9 sites in United States. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by Jasper Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
3 Months to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Immunologic Deficiency Syndromes with a site in United States — 27 open to participants now, 34 under way, none of them phase 3. Immunologic Deficiency Syndromes · United States.

Enrollment
40th of 77
23 · median 28
Started
2017
with 5 others
Phase 1/2
11 of 127
4 open now
Registered
87th of 127
by date

Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, this one is the 40th largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2017, is one of 11 in phase 1/2, and was the 87th registered.

Immunologic Deficiency Syndromes

204 studies on the registry are indexed under Immunologic Deficiency Syndromes; 50 are open to participants now.

Browse Immunologic Deficiency Syndromes studies →

Open to participants now

27 of the 127 studies in Immunologic Deficiency Syndromes with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger; 30 take children under 18; 10 take healthy volunteers.

This study: 3 Months to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Immunologic Deficiency Syndromes with a site in United States, or all of them as a file.
02

Study summary

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation

Read the detailed description

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with SCID undergoing blood stem cell transplantation. Blood Stem Cell transplantation offers the only potentially curative therapy for SCID.

The biological conditioning regimen, JSP191, is an antibody that binds to CD117. CD117 is the receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is critical for survival and maintenance of blood forming stem cells. The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells. In the absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that are currently occupying the bone marrow niches in SCID patients exit from the bone marrow.

03

Conditions studied

  • SCID

Keywords

  • Immunodeficiency
  • Pediatric
  • SCID
  • Bone Marrow Transplantation
  • GVHD
  • Stem Cells
  • Chimerism
  • Transplant
  • BMT
04

Who can participate

Ages eligible
3 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Typical SCID as defined by Primary Immune Deficiency Treatment Consortia including but not limited to the following subtypes:

    1. T-, B+, NK-: IL-2Rcγ deficient, JAK3-deficient (no longer enrolling)
    2. T-, B-, NK+: RAG1/2 deficient, Artemis-deficient
    3. T-, B+, NK+: IL7Rα deficient, CD3 subunit deficient, 5 deficient (no longer enrolling) OR Variant SCID with absent or low T cell function, Omenn syndrome, Leaky SCID, Reticular dysgenesis, Adenosine deaminase deficiency, and Purine nucleoside phosphorylase deficiency may be included after consultation with the medical monitor.
  2. Patients with human leukocyte antigen (HLA) matched related or unrelated donors
  3. Adequate end organ function as defined in study protocol
  4. Age ≤ 12 years
  5. Prior donor of appropriate age (≥ 5 years old) available for re-collection of stem cells
  6. Previous Hematopoietic Cell Transplantation HCT (≥ 6 months post initial transplant) with poor graft function

Key Exclusion Criteria:

  1. Patients with any acute or uncontrolled infections
  2. Patients receiving any other agents, or concurrent biological, chemotherapy, or radiation therapy
  3. Patients with active
  4. Active within 6 months prior to enrollment, or on therapy for GVHD
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Blood Stem Cell Transplant w/ anti-CD117 conditioning

    The study will enroll two groups: Group A: previously transplanted SCID patients; Group B: newly diagnosed SCID. The study plans to assess JSP191 in different dose cohorts. Patients will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.

    Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: Safety and tolerability of JSP191 as conditioning therapy in SCID patients undergoing HCT: adverse events

    The number of subjects experiencing dose limiting toxicities including adverse events and serious adverse events will be assessed.

    Time frame: Up to 5 years post Donor Cell Transplant (28 days dose limiting toxicity period)

  2. Phase 2: Efficacy of JSP191 as conditioning therapy in SCID patients

    To enable engraftment of allogeneic CD34+ hematopoietic cells, as determined by CD15+ donor myeloid chimerism

    Time frame: Up to 24 weeks post Donor Cell Transplant

  3. Phase 2: Efficacy of JSP191 as conditioning therapy in SCID patients

    To enable immune reconstitution, as determined by the production of naive T cells

    Time frame: Weeks 36-104 post Donor Cell Transplant

07

Study locations

9 sites
  • UCLA Mattel Children's Hospital
    Los Angeles, California 90095, United States
  • Lucile Packard Children's Hospital
    Palo Alto, California 94304, United States
  • UCSF Benioff's Children's Hospital
    San Francisco, California 94158, United States
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
08

References and documents

Individual participant data

Plan to share: No — Data collected is for future publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jul 2025, 99 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Nov 15, 2016
StartActual
Mar 20, 2017
Primary completionActual
Jul 7, 2025
CompletionActual
Jul 7, 2025
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02963064
Lead sponsor
Jasper Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Mar 20, 2017
Primary completion
Jul 7, 2025
Completion
Jul 7, 2025
Last update
Jul 28, 2025

Study contacts

Rajni A. Agarwal-Hashmi, M.D.
principal investigator · Lucile Packard Children's Hospital
Christopher C. Dvorak, M.D.
principal investigator · UCSF Benioff's Children's Hospital
Joseph H. Oved, M.D.
principal investigator · Memorial Sloan Kettering Cancer Center
Theodore B. Moore, M.D.
principal investigator · University of California, Los Angeles
Sharat Chandra, M.D.
principal investigator · Children's Hospital Medical Center, Cincinnati
Christen L Ebens, M.D., MPH
principal investigator · University of Minnesota
Harry L Malech, M.D.
principal investigator · National Institutes of Health Clinical Center (CC)
Shanmuganathan Chandrakasan, M.D.
principal investigator · Children's Healthcare of Atlanta
Neena Kapoor, M.D.
principal investigator · Children's Hospital Los Angeles
Elizabeth D Hicks, M.D.
principal investigator · Children's National Research Institute
Susan Prockop, M.D.
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Briquilimab

Start the discussion